NTLA has been the subject of several other research reports. Zacks Investment Research lowered Intellia Therapeutics from a buy rating to a hold rating in a research note on Thursday, August 8th. Chardan Capital reissued a buy rating and set a $57.50 price objective on shares of Intellia Therapeutics in a research note on Tuesday, May 28th. Roth Capital began coverage on Intellia Therapeutics in a research note on Monday, June 10th. They set a neutral rating and a $16.00 price objective for the company. ValuEngine lowered Intellia Therapeutics from a buy rating to a hold rating in a research note on Monday, August 26th. Finally, Robert W. Baird began coverage on Intellia Therapeutics in a research note on Monday, July 8th. They set an outperform rating and a $23.00 price target for the company. Eight research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. The stock currently has an average rating of Hold and a consensus price target of $25.56.
Shares of NASDAQ NTLA opened at $14.25 on Thursday. The stock has a market cap of $720.91 million, a PE ratio of -7.20 and a beta of 2.71. Intellia Therapeutics has a fifty-two week low of $11.03 and a fifty-two week high of $32.95. The company has a debt-to-equity ratio of 0.05, a quick ratio of 7.99 and a current ratio of 7.99. The stock has a fifty day moving average of $16.18 and a 200-day moving average of $16.04.
Intellia Therapeutics (NASDAQ:NTLA) last announced its quarterly earnings results on Thursday, August 1st. The company reported ($0.56) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.61) by $0.05. The company had revenue of $11.10 million during the quarter, compared to analysts’ expectations of $7.15 million. Intellia Therapeutics had a negative return on equity of 33.03% and a negative net margin of 242.65%. The firm’s quarterly revenue was up 44.2% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.52) earnings per share. On average, sell-side analysts predict that Intellia Therapeutics will post -2.29 EPS for the current year.
A number of hedge funds have recently modified their holdings of the business. Royal Bank of Canada lifted its stake in Intellia Therapeutics by 277.9% during the second quarter. Royal Bank of Canada now owns 133,723 shares of the company’s stock worth $2,189,000 after purchasing an additional 98,339 shares during the last quarter. Voloridge Investment Management LLC bought a new stake in shares of Intellia Therapeutics in the 2nd quarter valued at about $539,000. Nuveen Asset Management LLC bought a new stake in shares of Intellia Therapeutics in the 2nd quarter valued at about $2,416,000. UBS Asset Management Americas Inc. bought a new stake in shares of Intellia Therapeutics in the 2nd quarter valued at about $299,000. Finally, Balyasny Asset Management LLC lifted its stake in shares of Intellia Therapeutics by 25.6% in the 2nd quarter. Balyasny Asset Management LLC now owns 57,321 shares of the company’s stock valued at $938,000 after acquiring an additional 11,675 shares during the last quarter. 79.39% of the stock is owned by hedge funds and other institutional investors.
Intellia Therapeutics Company Profile
Intellia Therapeutics, Inc, a genome editing company, focuses on the development of therapeutics utilizing a biological tool known as the CRISPR/Cas9 system. The company develops in vivo programs focused on liver diseases, including transthyretin amyloidosis, alpha-1 antitrypsin deficiency, and primary hyperoxaluria.
Recommended Story: What does cost of debt say about a company’s financial health?
Receive News & Ratings for Intellia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.